Aytu BioPharma, Inc. and Lannett Company, Inc. mutually agreed to terminate their exclusive Metadate Agreement, effective June 23, 2026. Under the resulting Termination Agreement, Aytu BioPharma may continue selling and distributing existing Metadate CD inventory at its discretion, subject to ongoing royalty reporting and payments. For the quarter ended March 31, 2026, the company reported $49,000 in net revenue for Metadate CD. Aytu BioPharma is a biopharmaceutical company.